Tags

Type your tag names separated by a space and hit enter

Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study.
Nat Commun. 2023 Mar 29; 14(1):1746.NC

Abstract

Characterizing the long-term kinetics of maternally derived and vaccine-induced measles immunity is critical for informing measles immunization strategies moving forward. Based on two prospective cohorts of children in China, we estimate that maternally derived immunity against measles persists for 2.4 months. Following two-dose series of measles-containing vaccine (MCV) at 8 and 18 months of age, the immune protection against measles is not lifelong, and antibody concentrations are extrapolated to fall below the protective threshold of 200 mIU/ml at 14.3 years. A catch-up MCV dose in addition to the routine doses between 8 months and 5 years reduce the cumulative incidence of seroreversion by 79.3-88.7% by the age of 6 years. Our findings also support a good immune response after the first MCV vaccination at 8 months. These findings, coupled with the effectiveness of a catch-up dose in addition to the routine doses, could be instrumental to relevant stakeholders when planning routine immunization schedules and supplemental immunization activities.

Links

PMC Free PDF

Authors+Show Affiliations

Wang Q
Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Wang W
School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
Winter AK
Department of Epidemiology and Biostatistics, University of Georgia, Athens, GA, USA.
Zhan Z
Hunan Provincial Center for Disease Control and Prevention, Changsha, China.
Ajelli M
Laboratory for Computational Epidemiology and Public Health, Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA.
Trentini F
Dondena Centre for Research on Social Dynamics and Public Policy, Bocconi University, Milan, Italy.
Wang L
School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
Li F
Hunan Provincial Center for Disease Control and Prevention, Changsha, China.
Yang J
School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
Xiang X
Hunan Provincial Center for Disease Control and Prevention, Changsha, China.
Liao Q
School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
Zhou J
School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
Guo J
School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
Yan X
School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
Liu N
School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.
Metcalf CJE
Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA. Princeton School of Public and International Affairs, Princeton University, Princeton, NJ, USA.
Grenfell BT
Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA. Princeton School of Public and International Affairs, Princeton University, Princeton, NJ, USA.
Yu H
Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China. yhj@fudan.edu.cn. School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China. yhj@fudan.edu.cn.

MeSH

ChildHumansInfantAdolescentLongitudinal StudiesProspective StudiesMeaslesMeasles VaccineVaccinationAntibodies, ViralChina

Pub Type(s)

Journal Article

Language

eng

PubMed ID

36990986

Citation

Wang, Qianli, et al. "Long-term Measles Antibody Profiles Following Different Vaccine Schedules in China, a Longitudinal Study." Nature Communications, vol. 14, no. 1, 2023, p. 1746.
Wang Q, Wang W, Winter AK, et al. Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study. Nat Commun. 2023;14(1):1746.
Wang, Q., Wang, W., Winter, A. K., Zhan, Z., Ajelli, M., Trentini, F., Wang, L., Li, F., Yang, J., Xiang, X., Liao, Q., Zhou, J., Guo, J., Yan, X., Liu, N., Metcalf, C. J. E., Grenfell, B. T., & Yu, H. (2023). Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study. Nature Communications, 14(1), 1746. https://doi.org/10.1038/s41467-023-37407-x
Wang Q, et al. Long-term Measles Antibody Profiles Following Different Vaccine Schedules in China, a Longitudinal Study. Nat Commun. 2023 Mar 29;14(1):1746. PubMed PMID: 36990986.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study. AU - Wang,Qianli, AU - Wang,Wei, AU - Winter,Amy K, AU - Zhan,Zhifei, AU - Ajelli,Marco, AU - Trentini,Filippo, AU - Wang,Lili, AU - Li,Fangcai, AU - Yang,Juan, AU - Xiang,Xingyu, AU - Liao,Qiaohong, AU - Zhou,Jiaxin, AU - Guo,Jinxin, AU - Yan,Xuemei, AU - Liu,Nuolan, AU - Metcalf,C Jessica E, AU - Grenfell,Bryan T, AU - Yu,Hongjie, Y1 - 2023/03/29/ PY - 2022/07/02/received PY - 2023/03/13/accepted PY - 2023/3/31/medline PY - 2023/3/29/entrez PY - 2023/3/30/pubmed SP - 1746 EP - 1746 JF - Nature communications JO - Nat Commun VL - 14 IS - 1 N2 - Characterizing the long-term kinetics of maternally derived and vaccine-induced measles immunity is critical for informing measles immunization strategies moving forward. Based on two prospective cohorts of children in China, we estimate that maternally derived immunity against measles persists for 2.4 months. Following two-dose series of measles-containing vaccine (MCV) at 8 and 18 months of age, the immune protection against measles is not lifelong, and antibody concentrations are extrapolated to fall below the protective threshold of 200 mIU/ml at 14.3 years. A catch-up MCV dose in addition to the routine doses between 8 months and 5 years reduce the cumulative incidence of seroreversion by 79.3-88.7% by the age of 6 years. Our findings also support a good immune response after the first MCV vaccination at 8 months. These findings, coupled with the effectiveness of a catch-up dose in addition to the routine doses, could be instrumental to relevant stakeholders when planning routine immunization schedules and supplemental immunization activities. SN - 2041-1723 UR - https://www.unboundmedicine.com/medline/citation/36990986/Long_term_measles_antibody_profiles_following_different_vaccine_schedules_in_China_a_longitudinal_study_ DB - PRIME DP - Unbound Medicine ER -